Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-stage chronic kidney disease

Diabetes Research and Clinical Practice

Volumn 90, Issue 2, 2010, Pages 154-159

  Hayashino, Yasuaki ^a   Fukuhara, Shunichi ^a   Akizawa, Tadao ^b   Asano, Yasushi ^c   Wakita, Takafumi ^d,e   Onishi, Yoshihiro ^d   Kurokawa, Kiyoshi ^f  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Mito Red Cross Hospital   (Japan)

^d Institute for Health Outcomes and Process Evaluation Research   (Japan)

^e KANSAI UNIVERSITY   (Japan)

^f NATIONAL GRADUATE INSTITUTE FOR POLICY STUDIES   (Japan)

Author keywords

Chronic kidney disease; Cost effectiveness; Diabetes; Oral absorbent

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AST 120; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ADULT; AGE; ARTICLE; CHRONIC KIDNEY DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DIALYSIS; DRUG COST; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK REDUCTION; SENSITIVITY ANALYSIS; SIMULATION; STAGING; VASCULAR ACCESS;

ADMINISTRATION, ORAL; AGED; CARBON; COST OF ILLNESS; COST-BENEFIT ANALYSIS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY FAILURE, CHRONIC; OXIDES; QUALITY OF LIFE; RENAL INSUFFICIENCY, CHRONIC;

EID: 77957756092     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.07.007     Document Type: Article

References (33)

1. Gaster B., Hirsch I.B. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998, 158(2):134-140.
2. Parving H.H. Clinical experience in the treatment of diabetic renal disease (type 1 and 2): summary and concluding remarks. Kidney Int 1994, 45(Suppl.):165-166.
3. Parving H.H. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1994, 330(13):937-938.
4. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345(12):861-869.
5. Bertoni A.G., Krop J.S., Anderson G.F., Brancati F.L. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care 2002, 25(3):471-475.
6. Mokdad A.H., Bowman B.A., Ford E.S., Vinicor F., Marks J.S., Koplan J.P. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001, 286(10):1195-1200.
7. Mokdad A.H., Ford E.S., Bowman B.A., et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289(1):76-79.
8. Mokdad A.H., Ford E.S., Bowman B.A., et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000, 23(9):1278-1283.
9. Nakai S., Masakane I., Akiba T., et al. Overview of regular dialysis treatment in Japan as of 31 December 2006. Ther Apher Dial 2008, 12(6):428-456.
10. United States Renal Data System Patient mortality and survival. Am J Kidney Dis 1998, 32(2 (Suppl. 1)):S69-S80.
11. Ritz E., Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996, 27(2):167-194.
12. Aoyama I., Shimokata K., Niwa T. Combination therapy with benazepril and oral adsorbent ameliorates progressive renal fibrosis in uremic rats. Nephron 2002, 90(3):297-312.
13. Miyazaki T., Aoyama I., Ise M., Seo H., Niwa T. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrol Dial Transplant 2000, 15(11):1773-1781.
14. A study of AST-120 for evaluating prevention of progression in chronic kidney disease (EPPIC-1) 2008, ClinicalTrials.gov.
15. Akizawa T., Asano Y., Morita S., et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis 2009, 54(3):459-467.
16. Golan L., Birkmeyer J.D., Welch H.G. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999, 131(9):660-667.
17. Beck J.R., Kassirer J.P., Pauker S.G. A convenient approximation of life expectancy (the " DEALE" ). I. Validation of the method. Am J Med 1982, 73(6):883-888.
18. Beck J.R., Pauker S.G., Gottlieb J.E., Klein K., Kassirer J.P. A convenient approximation of life expectancy (the " DEALE" ). II. Use in medical decision-making. Am J Med 1982, 73(6):889-897.
19. Kunz K., Weinstein M. Modelling in economic evaluation. Economic evaluation in health care: merging theory with practice 2001, Oxford University Press, New York, NY. M. Drummond, M. McGuire (Eds.).
20. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis 2006, 48 (Suppl. 1):S2-S90.
21. Arias E. United States life tables, 2004. Natl Vital Stat Rep 2007, 56(9):1-39.
22. The Japanese Society for Dialysis Therapy The crude 1-yr mortality rates among hemodialysis patients 2008, Available at http://docs.jsdt.or.jp/overview/pdf2009/p021.pdf (accessed 14.06.10).
23. Gold M., Siegel J., Russel L., Weinstein M.C. Cost-effectiveness in health and medicine 1996, Saunders, Philadelphia.
24. The Diabetes Control and Complications Trial Research Group Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996, 276(17):1409-1415.
25. Lawrence W.F., Grist T.M., Brazy P.C., Fryback D.G. Magnetic resonance angiography in progressive renal failure: a technology assessment. Am J Kidney Dis 1995, 25(5):701-709.
26. Brown G.C., Brown M.M., Sharma S., Brown H., Gozum M., Denton P. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications 2000, 14(1):18-24.
27. Takahashi T., Reed S.D., Schulman K.A. Cost-effectiveness of the oral adsorbent AST-120 versus placebo for chronic kidney disease. Nephrology (Carlton) 2008, 13(5):419-427.
28. Japanese Ministry of Health Labour and Welfare Standard prices for medicines in 2008 2006, Shakai-hoken Kenkyujyo, Tokyo.
29. Rosen A.B., Hamel M.B., Weinstein M.C., Cutler D.M., Fendrick A.M., Vijan S. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 2005, 143(2):89-99.
30. Ellis J.J., Erickson S.R., Stevenson J.G., Bernstein S.J., Stiles R.A., Fendrick A.M. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004, 19(6):638-645.
31. Okada K., Shibahara H., Takahashi S. Effect of oral adsorbent on the progression of diabetic nephropathy. Nephron 1997, 76(4):489-490.
32. Aoyama I., Shimokata K., Niwa T. Oral adsorbent AST-120 ameliorates interstitial fibrosis and transforming growth factor-beta(1) expression in spontaneously diabetic (OLETF) rats. Am J Nephrol 2000, 20(3):232-241.
33. I. NKF-K/DOQI clinical practice guidelines for hemodialysis adequacy: update 2000. Am J Kidney Dis 2001, 37(1 (Suppl. 1)):S7-S64.